News

Corcept (NASDAQ:CORT) Reports Sales Below Analyst Estimates In Q4 Earnings

Biopharma company Corcept Therapeutics (NASDAQ:CORT) fell short of the market’s revenue expectations in Q4 CY2024, but sales rose 34.3% year on year to $181.9 million. On the other hand, the company’s full-year revenue guidance of $925 million at the midpoint came in 8.2% above analysts’ estimates. Its GAAP profit of $0.26 per share was 39% below analysts’ consensus estimates.

Marqeta’s (NASDAQ:MQ) Q4 Sales Beat Estimates, Stock Jumps 12.2%

Leading edge card issuer Marqeta (NASDAQ: MQ) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 14.3% year on year to $135.8 million. Guidance for next quarter’s revenue was better than expected at $135.7 million at the midpoint, 1.7% above analysts’ estimates. Its GAAP loss of $0.05 per share was in line with analysts’ consensus estimates.

Red Robin (NASDAQ:RRGB) Reports Q4 In Line With Expectations, Stock Jumps 11.4%

Burger restaurant chain Red Robin (NASDAQ:RRGB) met Wall Street’s revenue expectations in Q4 CY2024, but sales fell by 7.7% year on year to $285.2 million. On the other hand, the company’s full-year revenue guidance of $1.24 billion at the midpoint came in 1.5% below analysts’ estimates. Its non-GAAP loss of $0.94 per share was 63.8% below analysts’ consensus estimates.